Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paroxetine hydrochloride hemihydrate
Drug ID BADD_D01681
Description Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[A31914] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Indications and Usage Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]
Marketing Status approved; investigational
ATC Code N06AB05
DrugBank ID DB00715
KEGG ID D02260
MeSH ID D017374
PubChem ID 9843029
TTD Drug ID D06GDY
NDC Product Code 42858-705; 70518-1253; 71610-243; 42858-707; 63629-9498; 70518-0550; 73377-051; 70518-2376; 43547-348; 55700-503; 63187-927; 70518-2387; 43353-544; 55289-053; 63629-9499; 63629-9500; 0378-7003; 0378-7004; 70518-1406; 53296-0057; 42858-703; 43547-349; 50090-5987; 71205-527; 71610-204; 0615-7985; 62350-0044; 43353-554; 43547-350; 0378-7001; 0378-7002; 70518-2182; 70518-2598; 64220-113; 55289-037; 71205-198; 43547-347
UNII 41VRH5220H
Synonyms Paroxetine | Aropax | BRL-29060 | BRL 29060 | BRL29060 | FG-7051 | FG 7051 | FG7051 | Paroxetine Acetate | Seroxat | Paroxetine Hydrochloride Anhydrous | Paroxetine Maleate | Paroxetine, cis-(+)-Isomer | Paroxetine, cis-(-)-Isomer | Paroxetine, trans-(+)-Isomer | Paxil | Paroxetine Hydrochloride Hemihydrate | Paroxetine Hydrochloride, Hemihydrate | Paroxetine Hydrochloride
Chemical Information
Molecular Formula C19H23ClFNO4
CAS Registry Number 110429-35-1
SMILES C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4.O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Porphyria03.08.01.001; 14.14.01.001--Not Available
Priapism24.04.12.007; 21.03.01.005--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.006--
Pulmonary hypertension24.08.03.002; 22.06.01.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyuria20.08.02.016; 11.01.08.043--Not Available
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal pain20.02.03.003--Not Available
Respiratory disorder22.02.07.002--Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Salivary gland enlargement07.06.03.002--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Salpingitis21.14.03.001; 11.01.10.001--Not Available
Seborrhoea23.02.07.001--Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sialoadenitis11.01.04.002; 07.06.04.002--
Sinusitis11.01.13.005; 22.07.03.007--
Skin discolouration23.03.03.005--Not Available
Skin hypertrophy23.01.04.002--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.006--
Sputum increased22.02.03.007--Not Available
Status epilepticus17.12.03.005--Not Available
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages